GRCL
Gracell Biotechnologies Inc.
485.20$
-2.8%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | -100.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +7.8% | -0.3% | +35.8% | +21.4% | +13.3% | -3.9% | +13.9% | -15.2% | +21.5% | -24.5% | -13.2% | – | |
| – | +28.1% | -4.2% | +40.9% | -25.3% | +18.4% | -24.1% | +26.7% | -0.7% | -19.6% | +28.4% | -15.1% | – | |
| – | +13.7% | -1.5% | +37.4% | +6.2% | +14.4% | -8.7% | +16.4% | -12.1% | +11.6% | -15.3% | -13.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +53.4% | +14.3% | -22.9% | +21.9% | +7.4% | +16.3% | +12.5% | -3.9% | -7.5% | +2.9% | -24.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -92.1% | -27.3% | -37.5% | +30.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.